LUMOSA THERAPEUTICS ANNOUNCES POSITIVE RESULTS FROM LT3001(INTRAVENOUS ODATROLTIDE) PHASE 2B CLINICAL TRIAL IN ACUTE ISCHEMIC STROKE
Results presented at the 17th World Stroke Congress (WSC 2025) LT3001(Odatroltide)-202 phase…
AVITA Medical Announces CEO Transition
October 16, 2025 18:15 ET Â | Source: AVITA Medical Board Chairman Cary…
Advanced CAR-T Cell Therapy in a Young Engineer Battling High-Risk Pre-B Acute Lymphoblastic Leukemia
KOLKATA, India, Sept. 25, 2025 /PRNewswire/ -- In a major milestone for…
AVITA Medical to Host Investor Webinar Briefing
August 10, 2025 19:00 ET Â | Source: AVITA Medical VALENCIA, Calif., Aug.…
Connect Biopharma Presents Data Supporting Rademikibart at the European Academy of Allergy and Clinical Immunology (EAACI) 2025 Annual Congress
– Rademikibart significantly improved lung function and asthma control in patients with…